top of page
Latest News
Mexico vs Global Severe Asthma Study Shows Steroid Reduction Benefits and Need for Targeted Treatments
Long-term oral corticosteroid (LTOCS) use has been found to be lower in Mexican patients than globally and may be associated with impact to critical health outcomes, with potentially oral corticosteroid-related diseases found to be less common in Mexican patients. These findings are reported in the real-world study, “ Severe asthma patients’ characteristics in Mexico versus International Severe Asthma Registry (ISAR) Global ” , recently published in Current Allergy and Asthma
Mar 243 min read
Real-World Study Led by Observational and Pragmatic Research Institute Suggests GLP-1 Receptor Agonists May Reduce COPD Exacerbation Risk in Patients with Type 2 Diabetes
An international real-world study coordinated by the Observational and Pragmatic Research Institute (OPRI) suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with fewer exacerbations and reduced corticosteroid use in patients living with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D). The findings, published in Pragmatic and Observational Research , are based on data from a large UK primary care population. COPD and
Mar 232 min read
New Australian research identifies quality improvement program to reduce asthma and COPD exacerbations
The real-world observational study titled, " A 21-practice evaluation of an asthma and COPD quality improvement program ”, has found that the Achieving Clinical Audits Using Electronic Medical Records (ACAER) quality improvement program (QI), delivered by Optimum Patient Care (OPCA) in Australian primary care, may drive treatment change and reduce exacerbations among high-risk* asthma and COPD patients. Following the completion of the ACAER Asthma program, annual exacerbati
Nov 19, 20252 min read
Type 2 (T2)-targeted biologics have utility in the management of T2-low asthma, but more effective therapies are needed: Implications of EMBER study
The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated
Oct 14, 20253 min read
Cracking the Code: New ISAR Study Reveals How T2- and Non-T2 Inflammatory Pathways Predict Severe Asthma Exacerbations
A novel Bayesian Network analysis on the International Severe Asthma Registry (ISAR) has identified key clinical and biological pathways...
Jul 13, 20252 min read
Australian research identifies significant opportunity to reduce major cardiac and respiratory events in people with COPD, a leading cause of preventable hospitalisations
This real-world study of Australian primary care data shows that high-risk* COPD, characterised by recent breathing flare-ups, is...
Jun 26, 20253 min read
Breathing Easier: Our Quest to Transform COPD Management in Primary Care
Detailing the successful roll-out of our innovative quality improvement (QI) programme, CONQUEST, our latest article in Primary Health...
Jun 25, 20251 min read
Severe asthma biologic access criteria should consider long-term oral corticosteroid (LTOCS) users with low blood eosinophil counts (BEC): Implications of STAR study
The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...
Jun 11, 20253 min read
Minimizing Steroid Burden in Severe Asthma: Real-World Data Demonstrate Biologics as a Game Changer
Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...
Jun 3, 20253 min read
PREVAIL Trial Protocol: Early Intervention in Modifiable High-Risk COPD
Our latest manuscript in the Journal of the COPD Foundation describes the protocol for PREVAIL , the first clinical trial to test...
Jun 3, 20252 min read
Biologics for asthma prevent new-onset diabetes, major adverse cardiovascular events (MACE) as well as other oral corticosteroid (OCS)-related adverse events: Ground-breaking results from SOLAR II
The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...
May 19, 20254 min read
A recent study shows a surprising improvement in respiratory outcomes when patients with asthma receive weight loss drugs.
Singapore, [10 April 2025] – A large real world evidence study conducted by leading respiratory experts found patients with asthma who...
Apr 8, 20252 min read
Innovative analysis predicts steroid-related health risks for people with asthma
Singapore, [8 April 2025] – Groundbreaking research by the Observational and Pragmatic Research Institute (OPRI) has developed...
Apr 8, 20252 min read
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy: Results from CLEAR
A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...
Mar 18, 20253 min read
Global disease burden of patients with severe asthma, regardless of biologic accessibility and receipt of biologic treatment: Results from EVEREST
The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe...
Dec 16, 20243 min read
Exploring different composite definitions of responders to biologic treatment for severe asthma (FULL BEAM Response)
The International Severe Asthma Registry (ISAR) ’s new study, “ Exploring definitions and predictors of response to biologics for severe...
Jul 10, 20243 min read
Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults (FULL BEAM Remission)
We are excited to share groundbreaking findings on remission as a therapeutic target in " Exploring definitions and predictors of severe...
Jul 9, 20242 min read
International research collaboration affirms benefits of biologic therapies across broad severe asthma patient populations worldwide, but also highlights unmet treatment needs: Results from LUMINANT
Singapore, [25 June 2024] – A new analysis of data from the International Severe Asthma Registry (ISAR) has revealed a spectrum of...
Jun 25, 20243 min read
Ground-breaking new study from ISAR uncovers the power of asthma tests BEC and FeNO to predict effectiveness of biologic therapies in Severe Asthma
A new real-world research study from ISAR, the International Severe Asthma Registry , reveals the strength of the asthma tests...
May 8, 20242 min read
New ISAR Research Sheds Light on Asthma Exacerbation Rates: Great Variability Found Across Nations
The International Severe Asthma Registry is a global collaborative initiative to gather anonymous, longitudinal, real-life data for...
Apr 25, 20241 min read
bottom of page